Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Balixafortide + Eribulin or Nab-paclitaxel in HER2-negative Advanced Breast Cancer
NCT04826016Phase 2Withdrawn
- Sponsor
- MEDSIR
- Start
- Mar 2022
- Primary completion
- Mar 2022
- Modality
- Small Molecules, Modified Peptides
01
Overview
A Phase 2 trial of balixafortide in breast cancer, sponsored by MEDSIR. Planned start Mar 2022; status: withdrawn.
02
Drugs
balixafortide
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04826016.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04826016.